Newsfeeds Archive - Spark Newswire

5 minute read

Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session

May 8, 1:38 PM

Shares of Upstart Holdings, Inc. (NASDAQ:UPST) fell sharply during Wednesday’s session after the company reported first-quarter financial results…

AFIB

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

May 8, 12:31 PM

Gainers MaxCyte (NASDAQ:MXCT) shares rose 26.5% to $4.97 during Wednesday’s regular session. The company’s market cap stands at…

CLOV

3 minute read

Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday

By Avi Kapoor

May 8, 11:11 AM

U.S. stocks were mixed, with the Dow Jones gaining around 70 points on Wednesday. Shares of Louisiana-Pacific Corporation…

AMRC

2 minute read

Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday

By Avi Kapoor

January 9, 11:59 AM

U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday.

ACCD

1 minute read

Why Cell Engineering Company MaxCyte Shares Are Up Today

By Lekha Gupta

January 9, 11:35 AM

MaxCyte Inc (NASDAQ: MXCT) shares are trading higher by over 9% after the company disclosed strong preliminary Q4 and full-year

MXCT

1 minute read

Movers

12 Health Care Stocks Moving In Monday’s After-Market Session

By Benzinga Insights

January 8, 5:31 PM

Gainers Syra Health (NASDAQ:SYRA) shares rose 21.2% to $1.5 during Monday’s after-market session. The market value of their…

ATNF

2 minute read

MaxCyte Announces Preliminary Q4 Revenue $15.5M-$15.7M Vs $10.74M Est.; FY23 Revenue $41.1M-$41.3M Vs $36.72M Est.; Total Cash, Cash Equivalents, And Investments As Of December 31, 2023 Is Expected To Be ~$210M

By Benzinga Newsdesk

January 8, 5:08 PM

MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell

MXCT

4 minute read

MaxCyte Announces CEO Transition; Doug Doerfler, President And CEO, To Retire, Maher Masoud To Succeed, Effective Jan 1, 2024; Reiterating 2023 Core Revenue Guidance Of $28M-$30M Vs $35M Est. Expects To Exceed Prior SPL Program-Related Guidance Of $10M

By Benzinga Newsdesk

December 11, 5:11 PM

Doug Doerfler, President and CEO, to Retire Effective December 31, 2023; will continue to serve as an advisor to MaxCyte Maher Masoud, EVP, Head of Global Business Development and Chief Counsel, to Succeed Mr.

MXCT